logo-loader
viewOragenics Inc

Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial

Oragenics (NYSE:OGEN) CEO Alan Joslyn caught up with Proactive at the BIO Investor Forum in San Francisco. 

Joslyn says Oragenics is making 'great progress' enrolling patients in oral mucositis clinical trial. Oral mucositis is a painful side effect in patients who are receiving chemotherapy in head and neck cancers.

Quick facts: Oragenics Inc

Price: 0.453 USD

NYSE:OGEN
Market: NYSE
Market Cap: $20.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CleanSpark receives approval to list on the Nasdaq

CleanSpark Inc (OTCMKTS:CLSK) CEO Zach Bradford tells Proactive the advanced energy software and control technology company has managed to receive approval to list on the Nasdaq, hoping to reach enterprise software investors. Bradford says the Utah-based company hopes investors recognize the...

53 minutes ago

2 min read